You are here

Biphase Extended Release Tablet Formulation for Nerve Agent Pretreatment

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911QY-19-C-0010
Agency Tracking Number: C181-004-0040
Amount: $149,967.27
Phase: Phase I
Program: SBIR
Solicitation Topic Code: CBD181-004
Solicitation Number: 2018.0
Timeline
Solicitation Year: 2018
Award Year: 2019
Award Start Date (Proposal Award Date): 2018-10-15
Award End Date (Contract End Date): 2019-04-14
Small Business Information
104 T.W. Alexander Dr. Bldg 5 STE 505, P.O. Box 12072, Durham, NC, 27709
DUNS: 080123728
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Jason Zhou
 (919) 443-9421
 jason.zhou@zymeron.com
Business Contact
 Michael Liu
Phone: (919) 443-9421
Email: sbir@zymeron.com
Research Institution
N/A
Abstract
Given the unforeseen/unanticipated use of nerve agents in the battlefield and on the homeland, military personnel can benefit from this oncedaily pretreatment. It may also be desirable to pretreat certain medical and emergency aid personnel following a known/suspected nerveagent attack. Also, a novel, improved PB extended release formulations can be commercialized for the treatment of myasthenia gravis.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government